PARP抑制剂olaparib  

A PARP inhibitor: olaparib

作　　者：范丽萍[1,2] 焦园园[1] 李然[1] 郭子寒 张艳华[1] 

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [2]北京大学医学部药事管理与临床药学系,北京100191

出　　处：《中国新药杂志》2016年第12期1321-1325,共5页Chinese Journal of New Drugs

摘　　要：olaparib是一种聚腺苷二磷酸核糖聚合酶(PARP)抑制剂,能选择性地作用于BRCA突变阳性的肿瘤细胞,利用"协同致死性"机制使肿瘤细胞因双链DNA损伤无法修复而死亡。2014年12月,欧盟和美国先后批准其上市,用于治疗BRCA基因突变阳性的晚期卵巢癌患者,疗效显著,不良反应少,患者短期耐受性良好,具有广泛的应用前景。现对其药理作用、药动学、药物相互作用、临床试验以及不良反应等方面进行综述。olaparib is a kind of PARP inhibitor,which can selectively act on cancer cells with BRCA mutation and cause cancer cells death due to double-stranded DNA damage beyond repair by ＂collaborative deadly＂mechanism. In December 2014,the European Union and the United States approved the marketing of olaparib which is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. olaparib has significant effect,less adverse reactions,good tolerability,and wide application prospect. The pharmacological action,pharmacokinetics,drug interactions,clinical trials and adverse reactions of olaparib are reviewed in this article.

关 键 词：OLAPARIB 聚腺苷二磷酸核糖聚合酶抑制剂 卵巢癌 

分 类 号：R979.1[医药卫生—药品]